stoxline Quote Chart Rank Option Currency Glossary
  
Replimune Group, Inc. (REPL)
19.23  -0.58 (-2.93%)    11-19 16:00
Open: 19.89
High: 20.48
Volume: 1,687,260
  
Pre. Close: 19.81
Low: 19.18
Market Cap: 1,823(M)
Technical analysis
2026-11-20 7:49:39 AM
Short term     
Mid term     
Targets 6-month :  27.33 1-year :  31.92
Resists First :  23.4 Second :  27.33
Pivot price 20.76
Supports First :  15.53 Second :  10.67
MAs MA(5) :  20.4 MA(20) :  19.09
MA(100) :  13.81 MA(250) :  9.98
MACD MACD :  1.7 Signal :  2
%K %D K(14,3) :  51.4 D(3) :  65.3
RSI RSI(14): 55.1
52-week High :  23.4 Low :  1.5
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ REPL ] has closed above bottom band by 23.0%. Bollinger Bands are 0.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 20.54 - 20.65 20.65 - 20.74
Low: 18.84 - 19 19 - 19.12
Close: 19 - 19.23 19.23 - 19.42
Company Description

Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.

Headline News

Thu, 19 Nov 2026
Replimune Group, Inc. (REPL) Stock Price, News, Quote & History - Yahoo! Finance Canada

Wed, 18 Nov 2026
Wall Street Analysts Think Replimune Group (REPL) Could Surge 29.51%: Read This Before Placing a Bet - Yahoo Finance

Mon, 02 Nov 2026
Wall Street Analysts Believe Replimune Group (REPL) Could Rally 26.8%: Here's is How to Trade - Yahoo Finance

Thu, 24 Sep 2026
REPL Deadline Alert: SueWallSt Reminds Replimune Group, Inc. (REPL) Investors of Securities Class Action Deadline on October 5, 2026 - Morningstar

Thu, 10 Sep 2026
REPL Investor Alert: Replimune Group, Inc. Securities Class Action Notice - Contact SueWallSt - PR Newswire

Thu, 13 Aug 2026
REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky - Business Wire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 95 (M)
Shares Float 68 (M)
Held by Insiders 1.6 (%)
Held by Institutions 105 (%)
Shares Short 23,170 (K)
Shares Short P.Month 22,750 (K)
Stock Financials
EPS -2.79
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.16
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -44 %
Return on Equity (ttm) -115.9 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -2.78
Qtrly Earnings Growth 0 %
Operating Cash Flow -246 (M)
Levered Free Cash Flow -148 (M)
Stock Valuations
PE Ratio -6.9
PEG Ratio 0
Price to Book value 8.9
Price to Sales 0
Price to Cash Flow -7.43
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

Stoxline iOS

Alpha Bridge iOS

OptionCalc iOS

StockChart Android

Stoxline Android

Alpha Bridge Android

OptionCalc Android